Famous for the design and creation of functional human tissues for medical applications, we’ve recently also been following Organovo and other partnerships in researching human tissue as well as offering the first 3D bioprinted liver product.
It’s just been recently announced that Uniquest signed a worldwide licensing agreement with Organovo to patent kidney cells from induced pluripotent stem cells (iPSCs). Professor Melissa Little and her team at Uniquest have actually been able to grow kidney tissue which should prove to be helpful in not only drug screening but also disease modeling and cell therapy.
“When transcription profiles of kidney organoids were compared to human fetal tissues, they showed highest congruence with first trimester human kidney,” stated the researchers in their paper. “Furthermore, the proximal tubules endocytose dextran and differentially apoptose in response to cisplatin, a nephrotoxicant. Such kidney organoids represent powerful models of the human organ for future applications, including nephrotoxicity screening, disease modelling and as a source of cells for therapy.”
Together the teams will be working to develop the science, research, and development further of the kidney tissue.
“The mini-kidney we have been able to grow is very complex and more like the real organ,” Professor Little said. “This is important for drug testing as we hope these mini-kidneys will respond to the drugs as a normal organ might.”
Figure 2 from the paper: “Generating a kidney organoid equivalent to the human fetal kidney in vitro.”
While the mini-kidney is a huge step, it’s important to note that with the recent research, they have gone much further with developing kidney tissue. Organovo figures clearly into the picture as they will be using their famed bioprinting technology to separately develop a ‘kidney proximal tubule tissue’ that they project being released in 2016.
“We are excited to license this groundbreaking technology to enable the development of human kidney tissues that could change the landscape of drug testing and kidney research. Working with leading scientists such as Professor Little extends our leadership position in the generation and commercialization of tissues that better recreate in vivo human biology,” said Organovo’s Chief Technology Officer, Sharon Presnell, Ph.D.
Organovo will also continue to work with Professor Little in developing the intellectual property in extremely valuable and commercial applications for the kidney tissue, such as:
- Kidney disease modeling
- Nephrotoxicity screening
- Examining compounds to improve function in patients with renal disease
“This deal is anchored in world-leading induced pluripotent stem cell research by Professor Melissa Little and follows a research collaboration between The University of Queensland and Organovo, facilitated by UniQuest.,” said UniQuest CEO Dr. Dean Moss. “We are delighted to work with Organovo so that they can further develop and commercialise the technology to accelerate the drug discovery process and enable treatments to be developed faster and at lower cost.”
Figure 3 from the paper: “Kidney organoids contain differentiating nephrons, stroma and vasculature with progressive maturation with time in culture.”
This partnership is certainly one we’ll be following as Organovo will be granted development and commercialization rights for applications regarding in vitro while Uniquest will be receiving ‘technology access fees’ and royalty payments.
The paper ‘Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis‘ was authored by Minoru Takasato, Pei X. Er, Han S. Chiu, Barbara Maier, Gregory J. Baillie, Charles Ferguson, Robert G. Parton, Ernst J. Wolvetang, Matthias S. Roost, Susana M. Chuva de Sousa Lopes, and Melissa H. Little.
Let’s hear your thoughts on this partnership and what it may mean within the bioprinting space. Discuss in the Organovo / Uniquest forum thread on 3DPB.com.